Browsing: Mortality

Under optimistic scenarios, new research from Swiss Re projects that GLP-1 medications could reduce all-cause mortality in the US by as much as 6.4% by 2045. But what will the impact be on the life settlement market?

The success story of rising life expectancy is far from over, but it is evolving. For pensions and insurance, the challenge is to reflect short-term headwinds without losing sight of long-term potential.

Longevity and Mortality Investor (LMI) is the new name for Life Risk News. Greg Winterton caught up with Chris Wells, Managing Editor at LMI, to discuss the reasons behind the rebrand, his thoughts on how the longevity and mortality markets have evolved in recent years, and plans for the future.

A recent article in The Lancet Public Health suggests that walking 7,000 steps is associated with reductions in the risk of several serious health outcomes.

Two areas of research are providing the gerontology community with the most promise: dysregulated nutrient sensing and cell senescence.

Since the COVID-19 pandemic, a striking divergence has emerged in the UK. While pensioners are living longer, working-age adults are facing worsening mortality rates.

People with mental health conditions often suffer from worse physical health, have more age-related diseases, and have a lower average life expectancy than people without a mental illness.

At the end of June, the Continuous Mortality Investigation in the UK, which produces mortality data and analysis, issued its latest update, CMI_2024, which showed an increase in cohort life expectancies at age 65 in England and Wales.

CMI_2024 produces cohort life expectancies at age 65 that are about three months higher for males and about two weeks higher for females than in the previous version of the CMI model.

General mortality trend in England continues downwards but certain diseases getting worse.